India Challenges Pfizer to Perform Clinical Trial on Its Covid Vaccine, Pfizer Drops Out

Pfizer claims that its application was supported by data from a global study that showed an overall efficacy rate of 95% with no vaccine-related, serious safety concerns - but they were not willing to allow a new trial to prove it. -